Related Experiment Video

Updated: Jun 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Benefits, challenges, and registerability of the polypill

Peter Sleight1, Hubert Pouleur, Faiez Zannad

  • 1Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. peter.sleight@attglobal.net

European Heart Journal
|April 11, 2006
PubMed

Insights

The polypill, a single-pill combination, can improve cardiovascular disease (CVD) management by addressing multiple risk factors simultaneously. This approach enhances patient adherence and reduces the incidence of CVD.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) management emphasizes global risk reduction over individual risk factors.
  • High-risk patients often require multiple medications, potentially decreasing adherence and compliance.
  • Current treatment strategies face challenges in managing multiple cardiovascular risk factors effectively.

Purpose of the Study:

  • To review the benefits of the polypill in managing cardiovascular risk factors.
  • To discuss the challenges and requirements for successful polypill implementation and registration.
  • To explore the potential public health impact of polypill adoption.

Main Methods:

  • Literature review of existing studies on polypill efficacy and challenges.
  • Analysis of the potential impact of fixed-combination therapies on patient adherence.
  • Discussion of regulatory considerations for polypill approval.

Main Results:

  • Polypills offer a strategy to reduce multiple cardiovascular risk factors with a single daily dose.
  • Fixed-combination therapies have the potential to improve patient adherence and reduce pill burden.
  • Successful implementation requires balancing regulatory caution with public health benefits.

Conclusions:

  • Polypills represent a promising approach to improve cardiovascular risk factor management and reduce CVD incidence.
  • Addressing regulatory hurdles is crucial for realizing the public health benefits of polypills.
  • Further discussions with regulatory bodies are needed to facilitate polypill registration and adoption.

More Related Videos

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...